RxDoctor Payments Data

Camile Gooden, MD

Internal Medicine · Riverhead, NYNPI 1992092365

Payments from drug & device makers

$660in general payments, 2019–2025

Across 13 payments — averaging $50.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$150
  • AbbVie$144
  • Novo Nordisk$125
  • Nestle Healthcare Nutrition Inc.$111
  • GSK$49
  • Lilly USA, LLC$24
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer1$150
AbbVie(2 entities)4$144
Novo Nordisk1$125
Nestle Healthcare Nutrition Inc.1$111
GSK2$49
Lilly USA, LLC1$24
Johnson & Johnson1$20
Medtronic1$19
Amgen1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$109,999
Medicare patients
279
Services billed
1,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$69,903
EliquisApixaban29$38,615
JanuviaSitagliptin Phosphate20$29,369
MounjaroTirzepatide11$19,188
Praluent PenAlirocumab14$18,596
FarxigaDapagliflozin Propanediol15$18,389
Repatha SureclickEvolocumab16$17,808
SynthroidLevothyroxine Sodium55$4,825
Levothyroxine Sodium164$2,769
Metoprolol Succinate139$2,493
Pantoprazole Sodium141$2,313
Misoprostol12$1,479
Atorvastatin Calcium223$1,452
Metformin Hcl ErMetformin Hcl67$1,395
Rosuvastatin Calcium131$1,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$69,90342 claims
Lilly USA, LLCMounjaro$24$19,18811 claims
AbbVieSynthroid$144$4,82555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Riverhead

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →